γδ T细胞在结核病免疫治疗的研究及其应用前景

doi:10.3969/j.issn.1000-6621.2019.06.019

摘要/Abstract

摘要：

传统抗结核药物一般直接作用于结核分枝杆菌,在遏制结核病流行方面贡献巨大,但目前遇到了诸多障碍,亟需新的治疗策略。近年来“宿主靶向治疗”开始兴起,并显示有良好疗效,包括老药新用、细胞免疫治疗等;其中γδ T细胞的功能和作用日渐受到免疫学家和临床医师的重视。γδ T细胞是一类不同于αβ T细胞的T细胞亚群,其免疫治疗的安全性和有效性已经在抗肿瘤治疗的临床试验中得到确认。目前,动物实验及人类观察性研究已经证明γδ T细胞在调节结核病患者免疫反应方面有重要作用。笔者对宿主靶向治疗,尤其是γδ T细胞免疫治疗的现状,以及相关的基础研究和临床前研究进行综述,并提出进一步开发其抗结核治疗潜力的可能性。

关键词: 结核, T淋巴细胞亚群, 分子靶向治疗, 免疫疗法

Abstract:

Traditional anti-tuberculosis drugs, directly targeting on the Mycobacterium tuberculosis, have played important roles on controlling tuberculosis. However, new strategies for treatment are needed to solve the remaining problems. In recent years, “host-directed therapy”,including new use of old drugs and cell immunotherapies, has been reported to have exciting efficacy. The γδ T cell immunotherapy attracted especial attention by immunologists and clinicians. The γδ T cells are a subset of T cells, quite different from αβ T cells. The safety and efficacy of γδ T cell immunotherapy for cancer treatment have been confirmed in clinical trials. At present, studies on animal and human with tuberculosis have demonstrated that γδ T cells play important roles in immune response against tuberculosis. This review introduces current implications of host-targeted therapy, especially γδ T cell immunotherapy in tuberculosis treatment, and recent progresses of the basic research and preclinical studies on this new therapy, and also proposes potential possibilities in anti-tuberculosis treatment.

Key words: Tuberculosis, T-lymphocyte subsets, Molecular targeted therapy, Immunotherapy

付亮,梁娟,张国良,吴扬哲,邓国防. γδ T细胞在结核病免疫治疗的研究及其应用前景[J]. 中国防痨杂志, 2019, 41(6): 695-698. doi: 10.3969/j.issn.1000-6621.2019.06.019

Liang FU,Juan LIANG,Guo-liang ZHANG,Yang-zhe WU,Guo-fang DENG. γδ T cells in tuberculosis immunotherapy and future prospects[J]. Chinese Journal of Antituberculosis, 2019, 41(6): 695-698. doi: 10.3969/j.issn.1000-6621.2019.06.019

参考文献 51

[1]	World Health Organization . Global tuberculosis report 2018. Geneva: World Health Organization, 2018.
[2]	中国防痨协会. 耐药结核病化学治疗指南(2015). 中国防痨杂志, 2015,37(5):421-469.
[3]	World Health Organization . Treatment guidelines for multidrug- and rifampicin-resistant tuberculosis 2018 update. Geneva: World Health Organization, 2018.
[4]	Keshavjee S, Farmer PE . Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med, 2012,367(10):931-936. doi: 10.1056/NEJMra1205429 URL
[5]	Zumla A, Maeurer M, Chakaya J , et al. Towards host-directed therapies for tuberculosis. Nat Rev Drug Discov, 2015,14(8):511-512. doi: 10.1038/nrd4696
[6]	Cano-Muniz S, Anthony R, Niemann S , et al. New approaches and therapeutic options for Mycobacterium tuberculosis in a dormant state. Clin Microbiol Rev, 2018, 31(1). ii:e00060-17.
[7]	World Health Organization . Guidelines for treatment of drug-susceptible tuberculosis and patient care: 2017 update. Geneva: World Health Organization, 2017.
[8]	Mitchison D, Davies G . The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis, 2012,16(6):724-732. doi: 10.5588/ijtld.12.0083 URL
[9]	Tiberi S, du Plessis N, Walzl G , et al. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies. Lancet Infect Dis, 2018,18(7):e183-198.
[10]	Wallis RS, Hafner R . Advancing host-directed therapy for tuberculosis. Nat Rev Immunol, 2015,15(4):255-263. doi: 10.1038/nri3813
[11]	Wallis RS, Maeurer M, Mwaba P , et al. Tuberculosis-advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect Dis, 2016,16(4):e34-46. doi: 10.1016/S1473-3099(16)00070-0 URL
[12]	Lawand M, Dechanet-Merville J, Dieu-Nosjean MC . Key features of gamma-delta T-cell subsets in human diseases and their immunotherapeutic implications. Front Immunol, 2017,8:761. doi: 10.3389/fimmu.2017.00761 URL
[13]	Chien YH, Iwashima M, Kaplan KB , et al. A new T-cell receptor gene located within the alpha locus and expressed early in T-cell differentiation. Nature, 1987,327(6124):677-682. doi: 10.1038/327677a0
[14]	Vantourout P, Hayday A . Six-of-the-best: unique contributions of gammadelta T cells to immunology. Nat Rev Immunol, 2013,13(2):88-100. doi: 10.1038/nri3384
[15]	谈思怡, 向征, 徐艳 , 等. 人γδ T细胞的抗肿瘤临床免疫治疗新进展. 生命科学, 2017,29(9):855-863.
[16]	Holtmeier W, Kabelitzr D , gammade lta T cells link innate and adaptive immune responses. Chem Immunol Allergy, 2005,86:151-183.
[17]	Hayday AC .[gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol, 2000,18:975-1026. doi: 10.1146/annurev.immunol.18.1.975 URL
[18]	Jin Y, Xia M, Saylor CM , et al. Cutting edge: Intrinsic programming of thymic gammadeltaT cells for specific peripheral tissue localization. J Immunol, 2010,185(12):7156-7160. doi: 10.4049/jimmunol.1002781 URL
[19]	Kisielow J, Kopf M . The origin and fate of gammadeltaT cell subsets. Curr Opin Immunol, 2013,25(2):181-188. doi: 10.1016/j.coi.2013.03.002 URL
[20]	Wu YL, Ding YP, Tanaka Y , et al. gammadelta T cells and their potential for immunotherapy. Int J Biol Sci, 2014,10(2):119-135. doi: 10.7150/ijbs.7823 URL
[21]	Rei M, Pennington DJ, Silva-Santos B . The emerging protumor role of gammadelta T lymphocytes: implications for cancer immunotherapy. Cancer Res, 2015,75(5):798-802. doi: 10.1158/0008-5472.CAN-14-3228 URL
[22]	Kobayashi H, Tanaka Y . γδ T cell immunotherapy—A review. Pharmaceuticals (Basel), 2015,8(1):40-61. doi: 10.3390/ph8010040 URL
[23]	谢蕾, 陈稳, 王亮 , 等. γδ T细胞体外扩增方法的建立及其抗肿瘤活性. 中华肿瘤杂志, 2018,40(4):247-251.
[24]	李朝旭, 唐际存, 叶招明 . IFN-γ增强人γδ T细胞杀伤骨肉瘤细胞的研究. 南方医科大学学报, 2013,33(1):22-25.
[25]	闵宏林, 宋秀宇 . 结核杆菌抗原活化的γδ T细胞的抗肿瘤活性. 蚌埠医学院学报, 2000,25(5):321-323.
[26]	司力, 张明霞 . γδ T细胞与抗结核免疫. 安徽医学, 2007,28(3):278-279.
[27]	Kabelitz D, Bender A, Schondelmaier S , et al. A large fraction of human peripheral blood gamma/delta + T cells is activated by Mycobacterium tuberculosis but not by its 65-kD heat shock protein . J Exp Med, 1990,171(3):667-679. doi: 10.1084/jem.171.3.667 URL
[28]	代光明, 汪洪, 郑权 , 等. 卡介苗与结核分枝杆菌早期分泌靶抗原刺激人γ δ T细胞分泌细胞因子能力的比较. 中国生物制品学杂志, 2013,26(11):1567-1570.
[29]	代光明, 汪洪, 郑权 , 等. ESAT-6上调TLR-4通路增强人外周血γδ T细胞产生淋巴因子的实验研究. 重庆医学, 2014,43(13):1537-1539, 1542.
[30]	李丽, 乔丹, 劳穗华 , 等. 经卡介苗刺激后结核性胸腔积液中记忆性γδ T细胞的细胞因子水平及其受体表达. 中华结核和呼吸杂志, 2010,33(10):775-778.
[31]	Couzin-Frankel J . Breakthrough of the year 2013. Cancer immunotherapy. Science, 2013,342(6165):1432-1433. doi: 10.1126/science.342.6165.1432 URL
[32]	张巍, 景红梅, 王继军 , 等. 细胞免疫疗法对血液系统恶性肿瘤治疗作用的研究进展. 中国实验血液学杂志, 2017,25(3):941-946.
[33]	Barry R Bloom. Tuberculosis: Pathogenesis, protection, and control. Washington DC: ASM Press, 1994.
[34]	Chen ZW . Immune regulation of gammadelta T cell responses in mycobacterial infections. Clin Immunol, 2005,116(3):202-207. doi: 10.1016/j.clim.2005.04.005 URL
[35]	Boom WH . Gammadelta T cells and Mycobacterium tuberculosis. Microbes Infect, 1999,1(3):187-195. doi: 10.1016/S1286-4579(99)80033-1 URL
[36]	Brighenti S, Andersson J . Induction and regulation of CD8 + cytolytic T cells in human tuberculosis and HIV infection . Biochem Biophys Res Commun, 2010,396(1):50-57. doi: 10.1016/j.bbrc.2010.02.141 URL
[37]	Seder RA, Darrah PA, Roederer M . T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol, 2008,8(4):247-258. doi: 10.1038/nri2274
[38]	Han Q, Bagheri N, Bradshaw EM , et al. Polyfunctional responses by human T cells result from sequential release of cytokines. Proc Natl Acad Sci U S A, 2012,109(5):1607-1612. doi: 10.1073/pnas.1117194109 URL
[39]	Yao S, Huang D, Chen CY , et al. Differentiation, distribution and gammadelta T cell-driven regulation of IL-22-producing T cells in tuberculosis. PLoS Pathog, 2010,6(2):e1000789. doi: 10.1371/journal.ppat.1000789 URL
[40]	Li B, Rossman MD, Imir T , et al. Disease-specific changes in gammadelta T cell repertoire and function in patients with pulmonary tuberculosis. J Immunol, 1996,157(9):4222-4229.
[41]	Kaufmann SH, Lange C, Rao M , et al. Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review. Lancet Respir Med, 2014,2(4):301-320. doi: 10.1016/S2213-2600(14)70033-5 URL
[42]	陈勇, 李柏青 . 人γδ T细胞TCR分子与结核杆菌多肽抗原特异性结合的证据. 中华微生物学和免疫学杂志, 2005,25(1):15-20.
[43]	Dieli F, Troye-Blomberg M, Ivanyi J , et al. Vgamma9/Vdelta2 T lymphocytes reduce the viability of intracellular Mycobacterium tuberculosis. Eur J Immunol, 2000,30(5):1512-1519. doi: 10.1002/(ISSN)1521-4141 URL
[44]	Chen CY, Yao S, Huang D , et al. Phosphoantigen/IL2 expansion and differentiation of Vgamma2Vdelta2 T cells increase resistance to tuberculosis in nonhuman primates. PLoS Pathog, 2013,9(8):e1003501. doi: 10.1371/journal.ppat.1003501 URL
[45]	刘震天, 王兆华, 李柏青 . 结核患者外周血αβ T和γδ T细胞亚群免疫亚型细胞分布的探讨. 蚌埠医学院学报, 2017,42(2):141-144.
[46]	唐洁, 陈策, 查成 , 等. 肺结核患者外周血中结核分枝杆菌耐热抗原特异性的TNF-α~+γδ T细胞数量和亚群分析. 细胞与分子免疫学杂志, 2016,32(11):1527-1531.
[47]	虞胜镭, 邵凌云, 金嘉琳 , 等. 人类免疫缺陷病毒合并结核感染患者外周血Vγ2Vδ2 +T淋巴细胞的数量与功能变化 . 中华传染病杂志, 2009,27(7):413-417.
[48]	朱杰华, 罗军敏, 徐林 , 等. 结核性胸膜炎患者外周血和胸水γδ T和Th17细胞的频率变化及其意义. 免疫学杂志, 2013(2):142-146.
[49]	Campbell JJ, Brightling CE, Symon FA , et al. Expression of chemokine receptors by lung T cells from normal and asthmatic subjects. J Immunol, 2001,166(4):2842-2848. doi: 10.4049/jimmunol.166.4.2842 URL
[50]	El Daker S, Sacchi A, Montesano C , et al. An abnormal phenotype of lung Vγ9Vδ2 T cells impairs their responsiveness in tuberculosis patients. Cell Immunol, 2013,282(2):106-112. doi: 10.1016/j.cellimm.2013.05.001 URL
[51]	Qaqish A, Huang D, Chen CY , et al. Adoptive transfer of phosphoantigen-specific gammadelta T cell subset attenuates Mycobacterium tuberculosis infection in nonhuman primates. J Immunol, 2017,198(12):4753-4763. doi: 10.4049/jimmunol.1602019 URL